0|10000|Public
40|$|Gels {{are formed}} from silica powders and {{hydrochloric}} acid. The gels are then impregnated into a polymeric foam {{and the resultant}} sheet material is then used in applications where the transport of chloride ions <b>is</b> desired. <b>Specifically</b> <b>disclosed</b> <b>is</b> the utilization of the sheet in electrically rechargeable redox flow cells which find application in bulk power storage systems...|$|R
50|$|Five of the banks, {{which did}} not <b>specifically</b> <b>disclose</b> the {{conversion}} charge in their cardholder agreements, submitted that the charge {{was related to the}} exchange rate and not the interest rate posted on the monthly statements. The plaintiffs did not challenge the disclosure made by the four other banks.|$|R
40|$|A {{method of}} {{improving}} the separatory properties of membranes by the deposition of a fluorinated amphiphilic compound in an oriented Langmuir-Blodgett layer on the membrane surface so as to increase membrane selectivity and counteract membrane surface properties leading to fouling during liquid-liquid separations and enhance gas selectivities of membranes used for gas-gas separations. The use of a fluorinated long-chain pyridinium bromide <b>is</b> <b>specifically</b> <b>disclosed.</b> Georgia Tech Research Corporatio...|$|R
30|$|Gu and Li (2007) {{analyze the}} {{association}} of voluntary innovation strategy disclosure by high-tech firms and find on average positive stock price reactions following disclosure. Due to their specific focus, their results not only refer {{to the amount of}} disclosure given, but also to innovation strategy as <b>specifically</b> <b>disclosed</b> information. Finally, Knauer et al. (2012) provide evidence that voluntary forecast disclosures have an impact on share price, which increases with growing forecast reliability.|$|R
40|$|Systems {{and methods}} for joining BMG Composites <b>are</b> <b>disclosed.</b> <b>Specifically,</b> the joining of BMG Composites is {{implemented}} {{so as to}} preserve the amorphicity of their matrix phase and the microstructure of their particulate phase. Implementation of the joining method {{with respect to the}} construction of modular cellular structures that comprise BMG Composites is also discussed...|$|R
50|$|On July 10, 2008, the Anti-Corruption Commission (ACC) filed a {{case against}} Chowdhury in {{connection}} with concealing wealth worth Tk 1.38 million and amassing it illegally. Chowdhury denied the allegation. On November 18, 2008, Bangladesh High Court stayed the proceedings against her in the case which was again upheld by the Supreme Court on February 15, 2010. She was granted bail by the High Court. On November 29, 2010, High Court revoked {{the proceedings of the}} case on the ground that the charges against Chowdhury <b>were</b> not <b>specifically</b> <b>disclosed</b> in the case.|$|R
40|$|<b>Disclosed</b> <b>are</b> {{compounds}} comprising a benzenediol derivative {{bound to}} one or more fatty acids. Also <b>disclosed</b> <b>are</b> nutritional supplements, pharmaceutical formulations, delivery devices, and foodstuffs comprising the disclosed compounds. Methods of using the disclosed compounds and compositions to improve health <b>are</b> also <b>disclosed...</b>|$|R
40|$|Polymer-nanotube composites, fibers, and {{processes}} <b>Disclosed</b> <b>are</b> processes for preparing nanotube composite materials and fibers that provide exceptional nanotube alignment and dispersion. The disclosed processes include contacting nanotube dispersions with polymer melts. Also <b>disclosed</b> <b>are</b> nanotube composite fibers having high nanotube concentrations, exceptional nanotube alignment, and high thermal conductivity...|$|R
40|$|This study {{examines}} the voluntary disclosure of future earnings information in annual reports for Australian listed companies. We find that most Australian companies {{in our sample}} do not provide quantitative earnings, forecasts in their annual reports, although {{more than half of}} the sample do disclose forward-looking information relating to earnings, without <b>specifically</b> <b>disclosing</b> point estimates for the future. These companies mostly supply qualitative information with a positive bias, while the remainder of the sample discloses no forward-looking information relating to earnings. Our findings also suggest that larger companies with less volatile earnings tend to provide more future earnings information than smaller companies with relatively volatile earnings. Keywords...|$|R
50|$|Further {{specification}} {{of the information}} that can <b>be</b> <b>disclosed</b> <b>is</b> given by Statutory Instrument.|$|R
40|$|<b>Disclosed</b> <b>are</b> emissive {{materials}} of formula (I) or (II), comprising two bidentate NO-type ligands, or a tetradentate NOON-type ligand, and a transition metal. The emissive materials are useful as electrophosphorescent emitters in organic light-emitting devices. Also <b>disclosed</b> <b>are</b> methods for preparing organic light-emitting diodes comprising these emissive materials, {{and the use}} of such diodes as white and yellow organic light-emitting devices. published_or_final_versio...|$|R
40|$|<b>Disclosed</b> <b>is</b> a thermally-stable SnO 2 -surfaced {{polyimide}} film {{wherein the}} electrical conductivity of the SnO 2 surface {{is within the}} range of about 3. 0 x 10 (exp - 3) to about 1 x 10 (exp - 2) ohms(exp - 1). Also <b>disclosed</b> <b>is</b> a method of preparing this film from a solution containing a polyamic acid and SnCl 4 (DMSO) 2...|$|R
40|$|<b>Disclosed</b> herein <b>is</b> a novel {{antifungal}} compound, derivatives {{that are}} used b treat fungal infections. In a specific embodiment, the compound is a small molecule. In a specific embodiment, the compound described herein inhibits yeast to hypha transition under robust hyphal inducing conditions at lower concentration of the molecule. Also <b>disclosed</b> <b>is</b> a composition comprising the antifungal compound. In a specific embodiment, the composition is a pharmaceutical composition Also <b>disclosed</b> <b>is</b> a method of treating and/or preventing fungal infection using the disclosed compound. The disclosed compound exhibits antifungal activity against wide range of fungal species at slightly higher concentrations. Antifungal compound <b>disclose</b> d herein <b>is</b> use d as anti-biofilm agent against fungal infections. In a specific embodiment, the <b>disclosed</b> compound <b>is</b> effective for systemic fungal infections. In a certain embodiment, the <b>disclosed</b> compound <b>is</b> a broad-spectrum antifungal agent for treating topical local and/or systemic fungal infections. In a specific embodiment, the <b>disclosed</b> compound <b>is</b> used in the prevention or treatment of mycotic infections caused by various fungal pathogens. published_or_final_versio...|$|R
40|$|<b>Disclosed</b> <b>are</b> high {{surface area}} {{nanoparticles}} {{that have a}} fibrous morphology. The nanoparticles have a plurality of fibers, wherein each fiber is in contact with one other fiber and each fiber has a length of between about 1 nm and about 5000 nm. Also <b>disclosed</b> <b>are</b> applications of the nanoparticles of the present invention, and methods of fabrication of the nanoparticles of the present invention...|$|R
50|$|On {{the facts}} of the case, however, Lord Hope {{concluded}} that the information that <b>was</b> <b>disclosed</b> <b>was</b> relevant for the purpose for which the ECRC was required. Insufficient weight was given to the appellantâ€™s right to respect for her private life when the decision to <b>disclose</b> <b>was</b> made, however, this did not change the fact that the risk to the children outweigh the prejudicial effect of disclosure.|$|R
5000|$|December 7, 1999 Laus; Reiner, Ruegg; Curtis Landon, Wu; HongyuImmunostimulatory compositions. <b>Disclosed</b> <b>are</b> {{therapeutic}} compositions {{and methods}} for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also <b>disclosed</b> <b>are</b> expression vectors and systems for producing the polypeptide complexes.|$|R
40|$|<b>Disclosed</b> herein <b>are</b> nanoactuating rotaxanes {{comprising}} a threading component, the threading component comprising a oligoviologen, and {{at least}} two macrocylic components, wherein the oligoviologen is threaded through each of the macrocylic components. Also <b>disclosed</b> <b>are</b> methods for making and using the rotaxanes...|$|R
40|$|<b>Disclosed</b> <b>is</b> a thermally-stable SnO. sub. 2 -surfaced {{polyimide}} film {{wherein the}} electrical conductivity of the SnO. sub. 2 surface {{is within the}} range of about 3. 0. times. 10. sup. - 3 to about 1. times. 10. sup. - 2 ohms. sup. - 1,. Also <b>disclosed</b> <b>is</b> a method of preparing this film from a solution containing a polyamic acid and SnCl. sub. 4 (DMSO). sub. 2...|$|R
5000|$|February 27, 2001 Laus; Reiner, Ruegg; Curtis Landon, Wu; Hongyu Immunostimulatory method. <b>Disclosed</b> <b>are</b> {{therapeutic}} compositions {{and methods}} for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also <b>disclosed</b> <b>are</b> expression vectors and systems for producing the polypeptide complexes.|$|R
40|$|Carbon fiber {{reinforced}} {{carbon composite}} rotary sleeve, and disc valves for internal combustion engines {{and the like}} <b>are</b> <b>disclosed.</b> The valves <b>are</b> formed from knitted or braided or wrap-locked carbon fiber shapes. Also <b>disclosed</b> <b>are</b> valves fabricated from woven carbon fibers and from molded carbon matrix material. The valves of the present invention with their very low {{coefficient of thermal expansion}} and excellent thermal and self-lubrication properties do not present the sealing and lubrication problems that have prevented rotary sleeve and disc valves from operating efficiently and reliably in the past. Also <b>disclosed</b> <b>are</b> a sealing tang to further improve sealing capabilities and anti-oxidation treatments...|$|R
40|$|<b>Disclosed</b> herein <b>are</b> {{ionic liquid}} {{compositions}} comprising active pharmaceutical, biological, and nutritional compounds, {{and methods of}} use. Further <b>disclosed</b> <b>are</b> compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their use...|$|R
40|$|Ethynyl and {{substituted}} ethynyl-terminated polysulfones and {{a process}} for preparing the same <b>are</b> <b>disclosed.</b> These polysulfones <b>are</b> thermally cured to induce cross-linking and chain extension, producing a polymer system with improved solvent resistance and use temperature. Also <b>disclosed</b> <b>are</b> substituted 4 -ethynylbenzoyl chlorides as precursors to the substituted ethynyl-terminated polysulfones and {{a process for}} preparing the same...|$|R
5000|$|Another ligand {{that has}} <b>been</b> {{recently}} <b>disclosed</b> <b>is</b> shown below, claimed be a selective 5-HT5A agonist with Ki = 124 nM.|$|R
5000|$|Published {{accounts}} <b>are</b> only <b>disclosed</b> {{weeks or}} months after the year-end date, meaning that the information <b>disclosed</b> <b>is</b> already out of date.|$|R
40|$|Cell-based and {{cell-free}} assays <b>are</b> <b>disclosed</b> that detect {{compounds that}} promote aggregation of proteins, glycoproteins, and protein-nucleic acid complexes. Also <b>disclosed</b> <b>are</b> pharmaceutical formulations useful for treating or preventing viral infections, bacterial infections, cancer, and diseases involving hyper-proliferative cells. published_or_final_versio...|$|R
40|$|Cell based and {{cell-free}} assays {{for identifying}} compounds that promote aggregation of proteins, glycoproteins, and protein-nucleic acid complexes <b>are</b> <b>disclosed.</b> Also <b>disclosed</b> <b>are</b> compounds, formulations and {{methods for treating}} or preventing viral infection, bacterial infection, cancer, or diseases involving hyper-proliferative cells. published_or_final_versio...|$|R
40|$|<b>Disclosed</b> <b>are</b> {{embodiments}} for a {{tracking device}} having {{multiple layers of}} localization and communication capabilities, and particularly having the ability to operate in zero-infrastructure or zero-power conditions. Also <b>disclosed</b> <b>are</b> methods and systems that enhance location determination in zero-infrastructure and zero-power conditions. In one example, a device, system and/or method includes an infrastructure-based localization module, an infrastructure-less localization module and a passive module that can utilize {{at least two of}} the modules to determine a location of the tracking device...|$|R
40|$|<b>Disclosed</b> <b>are</b> microcapsules {{comprising}} a polymer shell enclosing {{two or more}} immiscible liquid phases {{in which}} a drug, or a prodrug and a drug activator are partitioned into separate phases. or prevented from diffusing out of the microcapsule by a liquid phase in which the drug is poorly soluble. Also <b>disclosed</b> <b>are</b> methods of using the microcapsules for in situ activation of drugs where upon exposure to an appropriate energy source the internal phases mix and the drug is activated in situ...|$|R
5000|$|August 19, 2008 Laus; Reiner, Ruegg; Curtis L., Shapero; Michael H., Yang; Demao Composition {{and method}} for {{producing}} an immune response against tumor-related antigens. <b>Disclosed</b> <b>are</b> a novel prostatic acid phosphatase and corresponding coding region derived from mouse. Also <b>disclosed</b> <b>is</b> {{a method of}} producing an immune response against an autologous polypeptide tumor antigen by immunizing a subject with a xenogeneic polypeptide antigen, either alone, {{as part of a}} viral antigen construct, or as part of a pulsed dendritic cell preparation.|$|R
6000|$|... "I left Miss Garth to decide--after warning her, {{first of}} all, that the {{circumstances}} I <b>am</b> compelled to <b>disclose</b> <b>are</b> {{of a very}} serious nature." ...|$|R
50|$|The <b>Discloser</b> <b>is</b> a 2017 South Korean drama film {{directed}} by Hong Ki-seon. The film stars Kim Sang-kyung, Kim Ok-bin, Choi Moo-sung and Choi Guy-hwa.|$|R
40|$|<b>Disclosed</b> <b>are</b> {{compounds}} of formula (l) -(V) : {{where the}} substituents are as provided herein. Further <b>disclosed</b> <b>are</b> methods of inhibiting tau aggregation, treating or ameliorating a tauopathy or cancer by administration of such a compound. Tau is a microtubule-binding protein that accumulates {{in a number of}} neurodegenerative disorders, including frontotemporal dementia and Alzheimer 2 Ì† 7 s disease (AD). The presence of abnormal tau correlates with neuron loss and memory deficits in patients with AD and other neurodegenerative disorders that involve tau accumulation...|$|R
40|$|<b>Disclosed</b> <b>are</b> {{methods and}} kits to treat HCV {{infection}} by administering an iminosugar derivative compound that is effective to inhibit {{the activity of}} HCV p 7 protein, and methods by which to screen for compounds that inhibit the activity of p 7 protein or variants thereof. The disclosed N-substituted imino compounds, and pharmaceutical compositions thereof, inhibit the capability of HCV p 7 to permeabilize membranes. Particularly efficacious compounds are imino sugars derived from N-alkylated piperidines. Also <b>disclosed</b> <b>are</b> methods for screening for potential HCV antiviral agents...|$|R
40|$|The first {{application}} of cinchona thioureas as organocatalysts in an oxidative process has <b>been</b> <b>disclosed.</b> <b>Specifically,</b> cinchona thioureas/tert-butyl hydroperoxide {{was found to}} be an effective system for an unprecedented asymmetric epoxidation of highly challenging deactivated 1, 1 -disubstituted alkenes. The corresponding terminal epoxides, bearing a quaternary stereogenic center, have been isolated in good to excellent yield (up to 98 %) and enantioselectivity (up to 99 % ee) by using 5 or 10 mol% of the organocatalyst...|$|R
50|$|The onus {{is on the}} {{employer}} to prove that any information that it has refused to <b>disclose</b> <b>is</b> not relevant for the purposes {{for which it is}} sought.|$|R
40|$|<b>Disclosed</b> <b>is</b> {{a method}} of {{estimating}} the state-of-charge of a rechargeable battery, {{taking into account the}} factors battery spread and ageing. The method comprises the steps of: determining the starting state-of-charge of the battery by measuring the voltage across the battery and converting this measured value into a state-of-charge value; charging the battery; integrating the charge current and determining the accumulated charge during charging of the battery and adding said value to the starting state-of-charge. Also <b>disclosed</b> <b>is</b> a method for determining the use time left of a rechargeable battery...|$|R
